Isofol Medical AB (publ) (STO:ISOFOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.675
-0.029 (-4.12%)
Apr 28, 2026, 5:29 PM CET
-64.45%
Market Cap 216.33M
Revenue (ttm) n/a
Net Income (ttm) -54.17M
Shares Out 320.49M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 514,754
Average Volume 996,920
Open 0.681
Previous Close 0.704
Day's Range 0.671 - 0.696
52-Week Range 0.552 - 2.294
Beta 0.87
RSI 47.49
Earnings Date May 19, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ISOFOL
Full Company Profile

Financial Performance

Financial Statements

News

Isofol Medical AB Transcript: Stora Aktiedagarna 2026

The presentation detailed a novel cancer drug's progress, highlighting strong early clinical results, a robust dose-response relationship, and a large unmet need in metastatic colorectal cancer. Expansion of clinical trials and strategic partnerships aim to accelerate development and commercialization.

7 weeks ago - Transcripts

Isofol Medical AB Transcript: Investor Update

Multiple clinical and financial milestones have been achieved, including a successful rights issue, FDA and Japanese regulatory progress, and a new patent extending exclusivity to 2043. The ongoing phase 1B/2 study is advancing with higher, well-tolerated doses and an improved design, supporting strong commercial and scientific potential.

5 months ago - Transcripts

Isofol Medical AB Earnings Call Transcript: Q2 2025

Exited the quarter with a strengthened financial position after an oversubscribed rights issue and continued progress in clinical trials. R&D expenses increased, resulting in a higher net loss, but positive regulatory feedback and new partnerships support future growth.

8 months ago - Transcripts